H.C. Wainwright analyst Andrew Fein downgraded Terns Pharmaceuticals (NASDAQ: TERN) from Buy to Neutral.The analyst comments "What’s new? Merck (MRK ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE